Fig. 2From: Oligo-recurrence predicts favorable prognosis of brain-only oligometastases in patients with non-small cell lung cancer treated with stereotactic radiosurgery or stereotactic radiotherapy: a multi-institutional study of 61 subjectsOverall survival (OS) stratified by oligostatus. The oligo-recurrence group has a significantly better OS than the oligometastases group. The oligo-recurrence group has an MST of 41 months independent of driver oncogenesBack to article page